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Drug repurposeIon channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion
channels. There are many clinically approved drugs with ion channels as “off” targets. The question is, can
these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only
save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques
and availability of a plethora of open access data on FDA approved drugs for various indications and omics
data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer
treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
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Cancer is the second most common cause of deaths in the United
States [1]. Cancer is characterized by sustained proliferation, resistance
to cell death, evasion of growth suppressors, angiogenesis, gain of
metastatic properties, and replicative immortality. These are famouslyne channels and transporters in
1 717 531 5013.called as hallmarks of cancer [2], additional two being evasion of
immune system and reprograming of cell metabolism [3]. During the
process of acquisition of these hallmarks cancer cells exploit a variety
of normal cellular signaling mechanisms and use functionally diverse
proteins. Amongst those, few are well studied while others are not.
Our understanding about the role of one such class of proteins called
membrane channels is in infancy. But available data strongly suggest
the critical role of membrane channels in cancer pathophysiology (for
detailed reviews refer [4,5]).
The role of ion channels in specialized excitable cells like neurons
and cardiac myocytes is very well known. Involvement of ion channels
2748 V.P. Kale et al. / Biochimica et Biophysica Acta 1848 (2015) 2747–2755in pathophysiology of various diseases/disorders has been studied and
drugs have been developed to cure those diseases. But an interest to
study the role of these channels in cancer pathophysiology was
triggered by seminal studies delineating the role of K+ channels in
mitogenesis [6] and oncogenesis [7]. This stimulated the search for pos-
sibility of targeting these ion channels to treat cancer [8–10]. Eventually
the ion channels became a point of discussion as a drug target culminat-
ing into a special colloquium on “Ion channels and Cancer” in 2007 [11].
Ion channels play critical roles in cancer pathophysiology by several
mechanisms. Ion channels like Ca2+, and Na+/K+ control cancer cell
proliferation by regulating several key survival signaling pathways
and membrane potential. A cancer cell undergoes changes in the cell
volume while progressing through various phases of cell cycle. Cell
volume is mainly regulated by ions like potassium, calcium, sodium
and chloride. Duringmigration, cancer cells use water current to propel
their body in conﬁned spaces [12]. Various ion channels along with
aquaporin play an important role in manipulating movement of water
molecules across the cell which propels the cells forward. This mecha-
nism is explained by the ‘osmotic engine model’ [12]. As per this
model, during cell migration NHE-1 (Na+/H+ exchanger-1) and AQP5
(aquaporin 5) are polarized at the leading edge. By using these ion
channels, cells allow in-ﬂow of water at the leading edge and out-ﬂow
at the trailing edge. This net turnover of water generates propulsive
force resulting into net displacement of the cell [12].
Readers can ﬁnd detailed roles of various ion channels in cancer path-
ophysiology elsewhere in this issue.Wehave summarized roles of various
ion channels in hallmarks of cancer and various tumors in Tables 1 and 2.
Despite their importance in cancer, there are hardly any drugs designed
speciﬁcally to target ion channels as cancer therapeutics. There are
many drugs primarily used to treat diseases like hypertension, psychiatric
disorderswhich are also inhibitors of ion channelswith different potency.
These clinically approved drugs can be repurposed for cancer indication
which will save time and signiﬁcant amount of money. Also these drugs
are in the clinic for a long period of time with known safety proﬁle.Table 1
Involvement of ion channels in hallmarks of cancer and potential therapeutic agents.
Hallmarks of cancer Membrane channels/transporters in
Cell growth 1. Cys-loop, cationic Ca2+ permeabl
2. Voltage gated Ca2+ (Cav): Cav1 L-
3. Voltage gated K+ (Kv): Kv10.1 (I)
4. Ca2+ activated K+ (KCa): KCa3.1
5. Inwardly rectifying K+ (Kir): Kir3
6. Background K+ (K2P): K2P2.1 (I),
7. TRP: TRPC6 (I), TRPV6 (I), TRPM7
Insensitivity to antigrowth signals 1. Purinergic, cationic Ca2+ permea
2. Voltage gated K+ (Kv): Kv11.1 (I)
3. Ca2+ activated K+ (KCa): KCa1.1
5. TRP, cationic Ca2+ permeable: TR
Evasion of apoptosis 3. Background K+ (K2P): K2P9.1 (D)
4. SOC, Ca2+ selective: Orai1 (D)
5. TRP, cationic Ca2+ permeable: TR
6. Cl− channels: CIC-3 (I)
Limitless replicative potential 1. Voltage gated Ca2+ (Cav): Cav1 (L
Angiogenesis 1. Voltage gated K+ (Kv): Kv10.1 (I)
2. Ca2+ activated K+ (KCa): KCa1.1 a
3. SOC, Ca2+ selective: Orai1 (I)
4. TRP, cationic Ca2+ permeable: TR
Metastasis 1. Voltage gated Na+ (Nav): Nav1.5
2. Voltage gated Ca2+ (Cav): Cav3.1
3. Voltage gated K+ (Kv): Kv11.1 (I)
4. Ca2+ activated K+ (KCa): KCa1.1 (
5. Inwardly rectifying K+ (Kir): Kir3
6. SOC, Ca2+ selective: Orai1 (I)
7. TRP, cationic Ca2+ permeable: TR
8. TRP, cationic Ca2+ permeable: TR
9. Na+ non-voltage-gated, DEG-rela
10. Cl− channels: CIC-3 (I)
Channel names are in IUPHAR nomenclature; I—increase; D—decrease.Repurposing of the approved drugs hasmanybeneﬁts in its basket to
offer such as:
1. Known safety proﬁle
2. Well understood pharmacokinetics in humans
3. Reduced time to repurpose the candidate from 10–17 years to
3–12 years [14]
4. Cost effectiveness. Can save large amount of money being spent on
early development
5. Since closer to the market authorization, easy to attract venture
capitalist to invest.
In general there are several different options for repurposing the
existing approved drugs [15]: A) Disease based approach is suitable
when we have very good information about pathogenesis (with omics
data) of a particular cancer.With omics information about the particular
cancer the FDA-approved drugs can be screened in silico to target the
key pathways: e.g. sunitinib for metastatic breast cancer. B) When we
have little information about a cancer type, FDA-off label screening is
a suitable method: e.g. rituximab for breast cancer. C) If we have
omics information about a particular drug (i.e. target information
about a drug), the drugs can be screened in relevant cancers with
dysregulation of those proteins: e.g. sirolimus for patients with
dexamethasone-resistant acute lymphoblastic leukemia. D) If we have
information of key protein/s in a cancer, FDA-approved drugs can be
screened for that particular target/s. Amongst these approaches, the
later two seem to be the most suitable for repurposing the drugs as
ion channel inhibitors (Fig. 1). However, not necessarily these ap-
proaches will be explored in isolation. Sometimes with available data,
more efﬁcient combined approaches may be taken. Jahchan et al. dem-
onstrated the effective way to identify existing FDA approved drugs for
new indications [16]. They used bioinformatics tools to identify poten-
tial candidate drugs for the treatment of small-cell lung cancer (SCLC)
from publicly available database of FDA approved drugs. They ﬁnally
narrowed down to a class of anti-psychotic drugs and identiﬁedvolved References
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Table 2
Major types of ion channels involved in pathophysiology of cancer and potential pharmacological modulators.
Family of membrane channels Class of membrane channels
involved in cancer
Cancer type Potential drugs Current indication or source (A/CT/PC/W) A= approved
CT= clinical trials
PC = preclinical
W=withdrawn
Cys-loop, cationic Ca2+ permeable nAChR α7 Small cell lung carcinoma [121] Memantine
α Conotoxin [149]
α Bungarotoxin [150]
Alzheimer's (A)
Cone snail toxin, Peripheral neuropathic pain (PC)
Krait toxin
Purinergic, cationic Ca2+-permeable P2X5/11, P2X7 Bladder [127], prostate [126] ATP [126,127] PC
Voltage-gated Na+ (Nav) Nav1.5, Nav1.7 Breast [142], prostate [143] CNV1014802, TV-45070, PF-05089771, DSP-2230
Ranolazin [151]
Riluzole [151]
Analgesic (CT)
Angina (A)
Amyotrophic lateral sclerosis (A)
Voltage-gated Ca2+ (Cav) Cav1 (L-type), Cav2.3 (R-type)
Cav3.1 (T-Type), Cav3.2 (T-Type)
Lung [99], ovarian [122,137], esophageal carcinoma
[94], prostate [97,152,153], fribrosarcoma [98], breast
[48,96,154], glioma [86,92], neuroblastoma [86],
colorectal, gastric, acute myelogenous leukemia [95],
retinoblastoma [93]
T-type: Mibefradil (T-Type) [86]
Pimozide [108]
Penﬂuridol [155]
KYS05041 [156]
TH-1177 [153]
L-type: Derivatives of dihydropyridine
(amlodipine, felodipine) [157]
Hypertension and angina pectoris (W)
Schizophrenia and Psychosis (A)
PC
Hypertension (A)
Voltage-gated K+ (Kv) Kv10, Kv11, Kv1.3 Breast, neuroblastoma, cervical [7], breast,
hepatocellular carcinoma, prostate carcinoma,
colon carcinoma, squamous cell lung carcinoma [23],
colon carcinoma [158], mammary
gland adenocarcinoma, neuroblastoma [25]
Margatoxin [159]
Verapamil [75–77]
TEA [75]
Tamoxifen [160]
E-4031 [161]
Kaliotoxin [162]
ShK-186 [26]
Astemizole [80]
Immunomodulation (PC)
Angina and arrhythmia (A)
PC
ER +ve Breast Cancer (A)
Arrhythmia (PC, hERG blocker)
Scorpion toxin (Kv1.3 blocker)
Sea anemone (PC for autoimmune diseases)
H1-receptor antagonist (W)
Ca2+ activated K+ (KCa) KCa1.1, KCa2.3, KCa3.1 Breast [41,48,163], cervical, ovarian [33], glioma [40],
melanoma [51]
Iberiotoxin [164]
Charybdotoxin [162]
Clotrimazole [165]
Scorpion toxin (PC)
Scorpion toxin (PC)-immunomodulation
Fungal infection (A)
Inwardly rectifying K+ (Kir) Kir3.1, Kir6.1 Breast [27,29,30,48], lung [28] Quinidine, linogliride [49]
Barium [166]
Arrhythmia (A)
Diabetic (A)
Diagnostic purpose (X-ray, CT Scan)
Background K+ (K2P) K2P2.1, K2P9.1 Prostate [31], breast [32], glioma [34] Vernakalant Atrial ﬁbrillation (halted in CT) [167]
SOC, Ca2+ selective Orai1/STIM1 Prostate [129,130,138], breast [144] Ophiobolin PC
TRP, cationic Ca2+ permeable TRPC1, TRPC3, TRPC4, TRPC6,
TRPV1, TRPV6, TRPM1, TRPM2,
TRPM7, TRPM8
Prostate [123,168,169], ﬁbrosarcoma [98], hepatocellular
carcinoma [145], gastric [131], breast [125]
Activators [170]: TRPM2:ADP-Ribose
TRPM8: Menthol, icilin, geraniol, eucalyptol
TRPV1: Capsaicin, anandamide, resiniferatoxin, ethanol
Inhibitors [170]: TRPM2: Clotrimazole [171]
TRPM8: SB-452533
TRPV1: Iodoresiniferatoxin, capsazepine
Clotrimazole is clinically used antifungal agent
Na+ non-voltage-gated, DEG-related ENaCα, ENaCγ, ASIC1, ASIC2 Glioblastoma [147], Glioma [148] Amiloride
Triamterene
Hypertension (A)
Cl− channels ClC-3 Prostate [133]
Gliomas [26]
Chlorotoxin [26]
Tamoxifen [172]
Scorpion toxin (CT)
Breast cancer (A)
Channel names are in IUPHAR nomenclature; A—approved for clinical use; W—withdrawn from market; CT—under clinical trials; PC—in preclinical trials.
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Fig. 1. Scheme for identiﬁcation and development of ion channel inhibitors by drug-repurposing.
2750 V.P. Kale et al. / Biochimica et Biophysica Acta 1848 (2015) 2747–2755imipramine, a tricyclic antidepressant, as a potential candidate by
in vitro assays and multiple mouse models. Imipramine found to be ef-
fective not only in ‘normal’ SCLC cells but also in ‘cisplatin-resistant’
SCLC cells. With this approach they could identify imipramine as a can-
didate drug for the treatment of SCLC and started Phase IIa clinical trials
in just 20months from the conception of this project [16]. This approach
not only saved several years of early drug discovery but saved millions
of dollars' investment in the drug development which will ultimately
beneﬁt the patients. Moreover, as this drug has been clinically used
for several decades, clinicians will have pretty good conﬁdence on its
toxicity and safety proﬁle. Additional few clinical studies for the new
indication of cancer will be able to take this drug to the patients.
Recently Amelio et al. developed a database, called DRUGSURV,
which provides statistical evidence for patient survival outcome data
of ~1700 approved and ~5000 experimental drugs [17]. This database
will further strengthen the computational drug repurposing. Addition-
ally, the Repurposing Drugs in Oncology (ReDo) project (http://www.
redo-project.org/) has systematically laid down the plan to identify
and develop new drugs for cancer treatment by repurposing the
approved drugs [18]. Such and other international collaborative group
efforts like NCGC Pharmaceutical Collection (NPC) [19] will hopefully
speed up the process of repurposing the drugs. Here we discuss the
possibility of repurposing some FDA-approved drugs as ion channel
inhibitors as cancer therapeutics. We discuss this with the examples of
targeting potassium and calcium channels. However, there is a vast
scope to repurpose drugs as inhibitors of other ion channels like sodium
and chloride as well.
2. Potassium (K+) channels
There are four structurally different K+ channel subfamilies involved
in cancer pathophysiology: voltage-gated (Kv), calcium activated (KCa),
inwardly rectifying (Kir), and two-pore-domain (background (K2P)
‘leak’) channels [20]. Amongst these Kv10.1 (EAG1) channels are
frequently upregulated in cancer cells and also extensively studied. K+
channels are the most diverse with 77 genes encoding it [20]. These
are the most frequently dysregulated channels in cancers. From such a
diverse family, any member can be dysregulated in a speciﬁc cancer inan individual. So, to be most effective, these different K+ channels
demand individual blockers. This leads to the possibility of using
personalized medicine. In order to treat effectively, we need to identify
which K+ channel is dysregulated in the particular patient and then
treat the patient with speciﬁc inhibitor of that K+ channel family mem-
ber. K+ channel family members like Kv10.1 are normally nearly absent
in organs other than the central nervous system, while they are
expressed in about 70% of tumors [10]. Hence these channels can be
speciﬁcally targeted in tumor tissueswith less toxicity in normal tissues.
2.1. Role K+ channels in the hallmarks of cancer
Seminal work by Decoursey et al. in 1984 indicated the possible role
of K+ channels in the mitogenesis of T-lymphocytes [21]. Further Pardo
et al. conﬁrmed involvement of Kv10.1 channels in oncogenesis by
showing upregulation of these channels in many cancer cells, prolifera-
tion inhibition after silencing of Kv10.1 expression and developing a
tumor with Kv10.1 overexpressed-CHO cells in SCID mice [7]. Thereaf-
ter, involvement of K+ channels in cancer pathophysiology is well stud-
ied. Rather K+ channels are one of the most studied ion channels in the
cancer ﬁeld. K+ channels have been shown to be involved in cancer cell
growth [7,22–32], conferring insensitivity to antigrowth signals [25,33],
evasion of apoptosis [34], angiogenesis [35–38] and metastasis [27,
39–43] in various cancers (Table 2). In MCF-7 breast cancer cells, the
cell membranes are in the depolarized state during the Go/G1 phase,
but they become hyperpolarized during the transition from G1 to S
phase [44,45]. On the contrary, in mouse early embryos, K+ channels
are inactive (depolarized state) during the transition of cells from G1
to S phase [46]. These opposite observations indicate that K+ channel-
mediated hyperpolarization (activation, opening of channels) and
depolarization (inactivation, closing of channels) of the cell membrane
during the cell cycle is speciﬁc to cell types. Also, it seems that speciﬁc
K+ channel family members play a role during different phases of cell
cycle. Kv10.1 channels are required for cancer cells to enter the G1
phase while KCa3.1 channels are required for progression from G1 to S
phase [11]. It is proposed that the role of K+ channels in the regulation
of cell cycle is not limited to the modulation of membrane potential only.
The role of K+ channels extends to the regulation of cell volume and
2751V.P. Kale et al. / Biochimica et Biophysica Acta 1848 (2015) 2747–2755calcium signaling during the progression of cells through cell cycle [47].
When K+ channels are blocked by speciﬁc blockers like quinidine, breast
cancer cells are arrested in the G1/G0 phase [44,48,49]. The role of K+
channels in the hallmarks of cancer and various cancer types is summa-
rized in Tables 1 and 2 respectively. For detailed recent reviews on role
of K+ channels in cancer, please refer [20,50].
2.2. Expression pattern of K+ channels in tumors
Kv10.1 is nearly absent in normal non-CNS tissues. However it has
been shown that Kv10.1 is overexpressed in many cancer cell lines like
breast, neuroblastoma, cervical carcinoma [7] melanoma [51] and
Kv11.1 (hERG) in human leukemic cell lines [52]. Overexpression of
Kv10.1 channels is also found in patient tumor tissues such as soft tissue
sarcoma (70%) [53], cervical cancer (100%) [54], Kv10.1 and Kv11.1 in
glioma [55], Kv11.1 in endometrial cancer [56] and Kv11.1 in chronic
lymphocytic leukemia compared to non-cancerous cells [52]. In
an extensive study on clinical tumor samples, Hemmerlein et al.
observed overexpression of Kv10.1 in 15/17 different types of can-
cers with more than 470 total samples studied [23]. Kv11.1 chan-
nels are also known to be upregulated in many cancers including
acute myeloid leukemia, breast, glioblastoma and colon cancers.
In addition to the regulation of potassium channels at the level of
gene expression, those are also regulated at the levels ofmRNA by editing
and alternate splicing, and post-translational modiﬁcations like
sumoylation [57,58], phosphorylation [59], glycosylation [60–62], and
palmitoylation [63].
2.3. K+ channel blockers
Most of the preclinical anticancer studies by potassium channel inhi-
bition are done on Kv10.1 [9,10,35], Kv10.2 (EAG2) [64] and Kv11.1 [65]
channels. Currently used antidiabetic sulfonylureas [66], antiarrhythmic
verapamil [67] and antiepileptic retigabine (ezogabine) [68] drugs are
also characterized for their inhibitory activity against potassium chan-
nels like KATP [69], Kv11.1 [70] and KCNQ [68] respectively. Sulfonylurea
drugs like glibenclamide are also effective against melanoma [71],
breast [72], lung [73] and gastric cancers [74] in preclinical studies.
Antiarrhythmic verapamil is effective against prostate cancer [75] and
neuroblastoma [76,77]. As verapamil is also a calcium channel inhibitor,
the anticancer effects of verapamil can be attributed to its combined
inhibitory activity against potassium and calcium channels. The explo-
rations of anticancer properties of antiepileptic drugs like retigabine
are at infancy phase. Preliminary studies showed that retigabine effec-
tively inhibits cell proliferation and cell migration of lung cancer cells
[78]. More in depth studies are needed to evaluate anticancer properties
of retigabine. Astemizole which was initially developed as H1-
anatagonist is now characterized for their Kv10.1 inhibition activity [79].
Hence astemizole can potentially be repurposed as an anticancer drug
[80,81]. However, existing data show that currently used potassium
channel blockers for various indications have a potential to be used as
anticancer therapeutics.
There are many approved K+ channel blockers used in the clinic for
various indications (Table 2). As an example, here we discuss the
approach for repurposing an antidepressant, imipramine, as an anticancer
therapeutic. However, this approach can be applied for other class of
drugs too. Imipramine is a tricyclic antidepressant developed by Ciba in
the late 1950s and marketed as Tofranil™. It is being used for the treat-
ment ofmajor depression symptoms for the last fewdecades. Imipramine
was initially known for its major inhibitory effect on serotonin reuptake,
norepinephrine reuptake and acetylcholine at the neural synapses in cen-
tral nervous system. However, the mechanisms of binding of imipramine
to Kv10.1 channels are now known [79,82]. In preclinical studies imipra-
mine inhibited proliferation of melanoma cells [83] and induced apopto-
sis in ovarian cancer cells [84]. By using bioinformatics-based drug
repositioning Jahchan et al. repurposed imipramine to treat incurablecisplatin-resistant small-cell lung cancer (SCLC), moving the drug into
clinical studies for this new indication [16]. In preclinical studies imipra-
mine induced apoptosis in SCLC cells. Though in this screening authors
identiﬁed imipramine drug for targeting GPCR receptors, inhibitory effect
of imipramine on Kv10.1 channels cannot be undermined [79,82]. The
major concern for repurposing such anti-psychotic drugs for cancer is
that they modulate one or more than one neurotransmitters like seroto-
nin, histamine, norepinephrine and acetylcholine with high potency.
Hence, such drugs need to be screened for their higher anti-cancer poten-
cy over antipsychotic use or if they can be prescribed cautiously to cancer
patients. Alternatively, efforts need to be made towards preventing such
drugs reaching to the brain by modifying non-pharmacophore or
changing the formulation and delivery methods to reduce neurological
‘off-target’ effects.3. Voltage-gated Ca (Cav) channels
3.1. Role of Cav channels in the hallmarks of cancer
Ca2+ ions have long been known as secondary messengers in
various cellular signaling including cell death and cell proliferation.
The fact that deprivation of extracellular Ca2+ leads to cell growth arrest
in G1/S indicates that Ca2+ is required for cell cycle progression.
Intracytoplasmic concentration of calcium is very strictly regulated by
various mechanisms. However discussion on cellular regulation and
signaling of calcium in cancer is beyond the scope of this article
(interested readers can refer to [85]). One of the calcium regulation
mechanisms is binding of calcium to calmodulin protein. Intracellular
calcium binds to calmodulin (CaM) II which in turn activates calcium-
calmodulin-dependent protein kinases and regulates pro-survival
transcriptional proteins such as cAMP response element, c-fos, c-jun
and serum response element [86]. Intracellular Ca2+ changes have dif-
ferential effects depending its duration, quantity and location. The Ca2+
concentration in the endoplasmic reticulum (ER) determines the fate of
the cells. Sustained increased concentration of Ca2+ in ER ([Ca2+]ER)
stimulates cell proliferation while decreased [Ca2+]ER slows down the
cell proliferation. But a sharp fall in the [Ca2+]ER or sustained decrease
in [Ca2+]ER, accompanied with release of ER-Ca2+ into the cytoplasm,
can induce apoptotic cell death [87]. Broadly classiﬁed, there are ﬁve
types of voltage gated calcium channels: T-, L-, P-, N-, and R-type.
Amongst these, T- and L-type are known to play a critical role in various
cancers. T-type channels are activated by small change in ion mem-
brane depolarization and are characterized by rapid inactivation,
while L-type are activated by strong depolarization and characterized
by slow inactivation [88]. Transient increased calcium levels are
required for the cells to transit from G1 and G2/M phases of the cell
cycle [89]. The expression of T-type channels increases in G2/M phase
while L-type channel expression increases in G0/G1 phase [90]. Oscilla-
tory expression of T-type Ca2+ channels during cell cycle indicates their
role in cell cycle progression. Activation of Ca2+ channels is supposed to
be downstream of depolarization of plasma membrane at G2/M phase
by inactivity of K+ channels [47,91]. This fact is very well represented
in “calcium oscillator model” [91].3.2. Expression pattern of Cav channels in tumors
T-type channels are more frequently involved in tumor cell prolifer-
ation and to some extent in metastasis (Table 2). T-type Ca2+ channels
play a signiﬁcant role in proliferation [92–97] andmigration/invasion of
various cancer cells/tumors [98]. However, the role of L-type Ca2+ chan-
nels or their overexpression has been reported in very few cancers like
lung adenocarcinoma [99]. Speciﬁc expression of T-type over L-type
channels in tumors supports the idea to target T-type channels as
potential cancer therapeutics.
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T-type calcium channel blockers (CCB) arrest the cell cycle in G1 or S
phase [100–102]. Cell cycle arrest sensitizes the cancer cells to cytotoxic
drugs. Currently available drugs are more effective when combined
with CCB [103]. Another advantage of the use of CCB is that they block
p-glycoproteins [104]. P-glycoproteins are responsible for conferring
multidrug resistance to the cancer cells. Hence the use of CCB makes
such cancer cells sensitive towards otherwise ineffective treatment.
Since increased intracellular Ca2+ triggers apoptosis, there can be
speculation that use of CCB will prevent cancer cells from dying. But
the clinical evidence does not support this causal relationship [105].
Mibefradil was approved as antihypertensive drug by FDA in 1997
and was marketed under trade name Posicor by Roche. It is a T- and
L-type Ca2+ channel blocker with greater speciﬁcity towards T-type
channels. Within a year, in 1998, it was voluntarily withdrawn from
market by Roche due to its interactions with around 25 other currently
prescribed medicines for different diseases. Mibefradil inhibits CYP450
2D6 and 3A4 along with p-glycoprotein [106,107]. This was one of the
main reasons for its withdrawal. Due to inhibition of CYP 3A4 and 2D6
bymibefradil, other drugswhich are co-administered do not getmetab-
olized in the liver and their blood concentrations rise leading to serious
toxicities. Taking into consideration of the role of T-type Ca2+ channels
in cancer pathology and its anticancer effect in various cancers including
glioblastoma [86], breast cancer and retinoblastoma cell lines [108],
with modiﬁcations it can be repurposed for cancer treatment. In an ef-
fort to overcome inhibitory effect on CYP450 3A4, Bui et al. developed
a derivative of mibefradil, NNC55-0396, which exhibits less inhibition
of CYP450 3A4 than its parent compound and also showsmore speciﬁcity
towards T-type Ca2+ channels [107]. Further, such modiﬁcations of
mibefradil to improve its CYP inhibitory proﬁle, keeping potential to in-
hibit p-glycoprotein, could accelerate the development of T-type Ca2+
channel blockers for cancer therapy, even in drug resistant cancers. TAU
Therapeutics LLC has repurposed mibefradil with Interlaced Therapy™
for high-grade glioma cancers (http://www.tautherapeutics.com/rd_
interlaced_therapy.php). In this approach, mibefradil is administered to
synchronize the cells in G1/S phase and then mibefradil is withdrawn
and standard chemotherapeutics, temozolomide, which active at S
phase, is administered to kill the cells. Alongwith cytostatic–cytotoxic ef-
fect, this also helps to overcome resistance of glioma cells to temozolo-
mide. This strategy is currently being validated in Phase 1b clinical trials.
This has shown an effective approach to repurpose existing drugs [109].
Nifedipine is one of the “WHO's essential medicines” indicated for
angina and hypertension. Nifedipine (Trade Names: Procardia™ and
Adalat CC™) has successfully been used in the clinic as antihypertensive
drug for the last several years with acceptable safety proﬁle. It is a
potent blocker of L-type Ca2+ channels. In vitro studies indicated that
nifedipine reduces mitogenic effect of endothelin 1 (ET1) by blocking
Ca2+ channels in lung cancer [99]. Nifedipine has shown to potentiate
pro-apoptotic effect of cisplatin in glioblastoma cells [110]. However,
its anticancer activity is disputed [111–113]. Since primary indication
of nifedipine is hypertension, it cannot be used in hypotensive cancer
patients. Nifedipine reduces the blood pressure rapidly causing
hypotensive shock. However, the alternate dosing systems like the con-
tinuous release system developed by Bayer (GITS—Gastrointestinal
Therapeutic System) may help to control the blood calcium levels and
avoid rapid hypotension [114].
Verapamil is an L-type Ca2+ channel blocker. Verapamil has shown
anti-proliferative effect in breast cancer in a mouse model [115], and
meningiomas [116] in a nude mouse model. In a prospective study of
99 patients with anthracycline-resistant metastatic breast carcinoma
verapamil showed positive survival effects [117]. In advanced
non-small lung cancer, verapamil improved survival of patients when
administered along with vindesine and ifosfamide [118]. However
there are contradictory reports about the anticancer properties of
verapamil. In human epidermoid carcinoma cells, dihydropyridinederivatives (amlodipine, nicardipine) showed anti-proliferative effect
while L-type Ca2+ channel blockers like verapamil and nifedipine did
not inhibit growth of cells [119]. In a Phase III clinical trial, addition of
verapamil to standard therapy (vincristine, doxorubicin and dexameth-
asone) for multiple myeloma did not have any beneﬁcial effect [120].
Such discouraging reports of effect of Ca2+ channel blockers and
increased susceptibility of hypertensive patients to breast cancer in a
10 year case–control study [113] warrant further investigations into
cancer speciﬁc Ca2+ channel inhibition by a speciﬁc inhibitor. However,
the later clinical case–control studywhere increased incidence of breast
cancer was noted is noteworthy; the study was done in hypertensive
patients which were being treated for hypertension.
4. Conclusion
Ions like K+, Ca2+ and Na+ undoubtedly play a signiﬁcant role in
various hallmarks of cancer. Different subtypes (like Kv10.1 and Kv11.1
and Ca2+ T- and L-type) of these channels play variable roles in different
cancers. In order to target these ion channels, it is important to under-
stand the expression pattern and signiﬁcance of expression of each of
those variants in a speciﬁc cancer type. Then there is a need of inhibitors
of those speciﬁc subtypes if ion channels. But there are hardly any drugs
developed speciﬁcally as ion channel inhibitors. Hence the alternate
and, cost- and time-effective strategy is to repurpose the currently
used drugs for other indications. As discussed in the above section,
repurposing of the approved drugs has many beneﬁts including
known safety proﬁle andwell understood pharmacokinetics in humans.
One of the biggest advantages of repurposing of the drug is to reduction
of time in approval. During 2003–2011 just 6.7% of oncology drugs
moved from Phase I to FDA approval [18]. Looking at such a slower
speed of drug approval, there is a dire need for repurposing the existing
drugs for cancer therapy. Advancement of bioinformatics tools with
open access database on cancer genome and proteome will ease the
process of repurposing. Strategic efforts like ReDo and collaborative
projects like NPC by international regulatory agencies will speed up
this process and stimulate research in this direction.
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